Niacinamide (Nicotinamide)
Niacinamide, also called nicotinamide, is the amide form of vitamin B3 and, with nicotinic acid (niacin), one of its two main forms in supplements. The body turns it into NAD+, a coenzyme used by more than 400 enzymes. Unlike nicotinic acid it does not cause flushing or change cholesterol levels. The daily requirement is only 14 to 16 mg, but research has used far larger doses. The best-known oral trial gave 500 mg twice daily for a year to people who had already had at least two non-melanoma skin cancers: fewer new lesions appeared than on placebo, but a later trial in transplant recipients found no difference. Small trials have tested 1 to 3 g a day on retinal function in people treated for glaucoma. Gram doses exceed US and EU upper limits and need medical supervision. Topical niacinamide creams are a separate topic not covered here.
Benefits
Vitamin B3 activity without the niacin flush
Niacinamide is a full form of vitamin B3 and counts toward the daily requirement (16 mg for men and 14 mg for women, as niacin equivalents). Unlike nicotinic acid, it does not cause skin flushing. It also does not change cholesterol levels, because it does not act on the receptors behind nicotinic acid's effects on blood lipids.
Sun-damaged skin in high-risk dermatology patients
In a 12-month trial of 386 adults who had already had at least two non-melanoma skin cancers, 500 mg twice daily lowered the rate of new non-melanoma skin cancers by 23% and of actinic keratoses (rough sun-damage patches) by 11 to 20% versus placebo. The difference disappeared after people stopped. These were high-risk patients under dermatologist care, so the result is not evidence for people without that history.
Skin results in later trials and pooled analyses
A trial of the same dose in 158 organ-transplant recipients, stopped early because of slow recruitment, found no fewer skin cancers or actinic keratoses than placebo. Two meta-analyses disagree: one rated the overall reduction in skin cancers as moderate-certainty evidence, while a later one, pooling fewer trials, judged the evidence insufficient.
Skin immune response to UV light in healthy volunteers
In a crossover trial in healthy volunteers, one week of 500 or 1,500 mg daily lessened the drop in skin immune responses caused by low doses of simulated sunlight. Two later 30-day studies at 2,000 mg daily, with no placebo group, gave mixed results: no protection against UVB redness or DNA damage, and less UVA redness without less DNA damage. It is not a substitute for sunscreen.
Inner retinal function in eye-clinic studies
In two placebo-controlled crossover trials in people already treated for glaucoma (57 and 53 participants), 12 weeks at 1 to 3 g daily improved electrical signals from the inner retina, measured by electroretinography: on nicotinamide but not on placebo in one trial, and more than on placebo in the other. Visual-field results were weaker, with a possible gain in one trial and no significant difference in the other.
NAD+ precursor role
The body converts niacinamide into NAD+, the coenzyme behind energy metabolism and DNA maintenance. In a 14-day trial in 65 healthy adults, 500 mg daily caused only a brief rise in blood NAD+ markers after each dose and did not raise circulating NAD+ over two weeks, unlike nicotinamide riboside (NR) and NMN at 1 g daily.
Mechanism of action
Feeds the NAD+ salvage pathway
Absorbed niacinamide is converted into NAD+ and NADP+, coenzymes that carry electrons in energy metabolism and that DNA-repair and signalling enzymes consume. The liver methylates any excess into N1-methyl-nicotinamide and related compounds, which are excreted in urine. In a human trial, a daily dose caused only a brief rise in blood NAD+ markers rather than a sustained one.
Supports skin-cell energy and DNA repair after UV (lab work)
In skin cells grown in the lab and in donated human skin samples, nicotinamide helped cells keep up their energy supply after UV exposure and sped the repair of two types of UV-induced DNA damage. These are laboratory findings; a later study in healthy volunteers taking 2,000 mg daily did not detect less UV-induced DNA damage in skin.
No action on the niacin lipid receptor
Nicotinic acid changes blood lipids by binding specific receptors and also causes flushing. Niacinamide does not bind the receptors behind the lipid effects and does not cause flushing, which is why it has a different benefit and side-effect profile from niacin and is not a cholesterol treatment.
Clinical trials
Phase 3, double-blind, randomized, placebo-controlled trial of nicotinamide 500 mg twice daily for 12 months, with dermatologist skin checks every 3 months for 18 months; funded by Australia's National Health and Medical Research Council (Chen et al. 2015, N Engl J Med).
386 Australian adults who had had at least two non-melanoma skin cancers in the previous 5 years.
At 12 months the rate of new non-melanoma skin cancers was 23% lower than placebo (95% CI 4 to 38, P=0.02). Basal-cell carcinomas were 20% lower (not significant, P=0.12) and squamous-cell carcinomas 30% lower (P=0.05). Actinic keratoses were 11 to 20% lower at each 3-month check. Adverse events were similar, and there was no benefit after the tablets were stopped. A high-risk patient group, not evidence for healthy people.
Phase 3, randomized, placebo-controlled trial of nicotinamide 500 mg twice daily for 12 months; stopped early because of poor recruitment (Allen et al. 2023, N Engl J Med).
158 immunosuppressed solid-organ transplant recipients who had had at least two keratinocyte skin cancers in the past 5 years.
There were 207 new keratinocyte cancers on nicotinamide and 210 on placebo (rate ratio 1.0, 95% CI 0.8 to 1.3, P=0.96). Squamous-cell, basal-cell and actinic keratosis counts and quality of life also did not differ. Adverse events and blood and urine tests were similar in both groups. The primary outcome was null.
Systematic review and meta-analysis of randomized controlled trials of nicotinamide by any route and for any indication, searched to October 2020 (Mainville et al. 2022, J Cutan Med Surg).
29 trials with 3,039 patients overall; 5 trials (552 patients) reported skin-cancer counts.
Nicotinamide was linked to fewer skin cancers than control (rate ratio 0.50, 95% CI 0.29 to 0.85; moderate strength of evidence, with heterogeneity explained by risk of bias). Effects on actinic keratoses and melanoma were not significant. Digestive side effects were more common with nicotinamide (risk ratio 1.78, very low certainty), while skin and laboratory side effects did not differ from control. A later meta-analysis that pooled fewer trials found the skin-cancer evidence insufficient.
Randomized, double-blind, placebo-controlled crossover study using the Mantoux skin-immunity model after low-dose solar-simulated UV on 3 consecutive days (Yiasemides et al. 2009, Carcinogenesis).
Healthy volunteers taking nicotinamide (500 or 1,500 mg daily) or placebo for 1 week each.
On placebo, UV suppressed the skin's immune reaction in a dose-dependent way; both nicotinamide doses significantly reduced this suppression, with no effect on immune reactions in skin that was not irradiated. Nicotinamide was well tolerated. This is a short experimental skin measure, not a test of sunburn or skin health over time.
Double-masked, randomized, placebo-controlled crossover trial at two tertiary eye centres, with no washout between periods (Hui et al. 2020, Clin Exp Ophthalmol).
57 people diagnosed with and already treated for glaucoma; nicotinamide 1.5 g/day for 6 weeks then 3.0 g/day for 6 weeks, or placebo.
The main electroretinogram measure (PhNR Vmax) improved by 14.8% within the nicotinamide period (P=0.02) versus 5.2% within the placebo period (not significant), and the Vmax ratio by 12.6% versus 3.6%. In visual-field testing, 27% improved by at least 1 dB on nicotinamide and fewer worsened than on placebo (P=0.02), which the authors called a trend. Short-term functional measures in patients on standard treatment, not evidence of slowed disease.
Double-masked, placebo-controlled, randomized crossover trial without washout; funded by Hanlim Pharm, and one co-author is a named inventor on a patent for nicotinamide treatment in glaucoma (Ha et al. 2026, Br J Ophthalmol).
53 people with normal-tension glaucoma already on eye-pressure-lowering treatment; nicotinamide 1 g/day for 6 weeks then 2 g/day for 6 weeks, or placebo.
After 12 weeks, two electroretinogram amplitudes (PhNR peak-to-trough and B-wave) rose more on nicotinamide than placebo (P=0.045 and P=0.032). Visual-field measures (mean deviation, pattern standard deviation and visual field index) did not differ between groups. Small, short and in patients.
Randomized, open-label, placebo-controlled study by Nestle researchers comparing three NAD+ precursors over 14 days (Christen et al. 2026, Nat Metab).
65 healthy adults (mean age about 35) analysed; nicotinamide 0.5 g/day (17 people), NR 1 g/day, NMN 1 g/day or placebo.
After 14 days, NR and NMN raised circulating NAD+ to a similar degree, but nicotinamide did not. Nicotinamide was the only precursor that acutely and briefly changed the whole-blood NAD+ metabolome after a dose. Each nicotinamide dose also briefly raised blood homocysteine, which the authors linked to its methylation. Industry-run and open-label, and it measured blood markers, not health outcomes.
Randomized, double-blind, placebo-controlled trial in 18 European countries, Canada and the USA testing modified-release nicotinamide 1.2 g/m2 of body surface per day for 5 years (Gale et al. 2004, Lancet).
552 first-degree relatives of people with type 1 diabetes who had islet-cell antibodies but normal glucose tolerance.
Diabetes developed in 82 people on nicotinamide and 77 on placebo (adjusted hazard ratio 1.01, P=0.97), so the primary outcome was null. Serious adverse events did not differ between groups, and nicotinamide did not affect children's growth or first-phase insulin secretion. Its main value here is long-term safety data at gram doses.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Niacinamide (Nicotinamide)
Is niacinamide the same as niacin?
Both are vitamin B3 and both cover your daily requirement, but they behave differently at high doses. Niacin (nicotinic acid) causes flushing and changes cholesterol levels; niacinamide does neither. Niacinamide is therefore not a substitute for prescribed niacin, and niacin is not what was tested in the skin and eye studies.
Will niacinamide make me flush?
No. Flushing is caused by nicotinic acid, not by niacinamide, so check the label to see which form of vitamin B3 a product contains.
How much niacinamide is safe to take?
The requirement is only 14 to 16 mg a day. The US upper limit for supplemental niacin, which covers niacinamide, is 35 mg a day, and the EU limit for nicotinamide is 900 mg a day for adults. The 1,000 mg a day used in skin trials is above both, so take gram doses only with a doctor's advice, especially if you have liver or kidney disease, are pregnant or breastfeeding, or take seizure medicines.
I have had skin cancer before. Should I take niacinamide?
That is a question for your dermatologist. One large trial in people with at least two previous non-melanoma skin cancers found fewer new lesions during a year of 500 mg twice daily, but a trial in transplant recipients did not, and the effect stopped when the tablets stopped. Niacinamide does not replace sun protection or regular skin checks.
Does niacinamide raise NAD+ like NR or NMN?
It is an NAD+ precursor, but in a 14-day head-to-head study in healthy adults, 500 mg of nicotinamide a day did not raise circulating NAD+, while 1 g of NR or NMN did. Nicotinamide caused only a brief change after each dose.
What is Niacinamide?
Niacinamide, also called nicotinamide, is the amide form of vitamin B3 and, with nicotinic acid (niacin), one of its two main forms in supplements. The body turns it into NAD+, a coenzyme used by more than 400 enzymes. Unlike nicotinic acid it does not cause flushing or change cholesterol levels.
What is Niacinamide used for?
Niacinamide is researched primarily for Hair, Skin & Nails and Eye Health. Niacinamide is a full form of vitamin B3 and counts toward the daily requirement (16 mg for men and 14 mg for women, as niacin equivalents). Unlike nicotinic acid, it does not cause skin flushing.
Is Niacinamide safe, and does it have side effects?
Side effects and cautions reported for Niacinamide include: Does not cause the skin flushing seen with nicotinic acid (niacin), and has fewer side effects, which typically begin only at much higher doses. Digestive upset: a meta-analysis of 21 trials found digestive side effects about 1. It may also interact with some medications. Niacinamide is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Niacinamide interact with any medications?
Possible interactions include: Carbamazepine and primidone (seizure medicines): nicotinamide raised carbamazepine levels in two patients and slowed primidone metabolism, probably by inhibiting liver enzymes. Do not start gram doses without asking your prescriber, who may check drug levels. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Niacinamide?
NutraSmarts rates the evidence for Niacinamide as Moderate (3 out of 5). It is backed by 8 study summaries and 16 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(16 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-26. doi: 10.1056/NEJMoa1506197.PubMedUsed to support: Phase 3 randomized, placebo-controlled trial (ONTRAC) in 386 adults with at least two prior non-melanoma skin cancers: nicotinamide 500 mg twice daily for 12 months lowered the rate of new non-melanoma skin cancers by 23% and reduced actinic keratoses, with similar adverse events; there was no benefit after stopping.
- Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med. 2023;388(9):804-812. doi: 10.1056/NEJMoa2203086.PubMedUsed to support: Phase 3 placebo-controlled trial (ONTRANS) in 158 organ-transplant recipients, stopped early for poor recruitment: 500 mg twice daily for 12 months did not reduce keratinocyte skin cancers (rate ratio 1.0) or actinic keratoses; adverse events and lab tests were similar.
- Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis. J Cutan Med Surg. 2022;26(3):297-308. doi: 10.1177/12034754221078201.PubMedUsed to support: Meta-analysis of 29 randomized trials (3,039 patients): nicotinamide was linked to fewer skin cancers (rate ratio 0.50, 5 trials, moderate strength of evidence) but not to fewer actinic keratoses, and to more digestive side effects (risk ratio 1.78, very low certainty).
- The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis. Nutrients. 2023;16(1):100. doi: 10.3390/nu16010100.PubMedUsed to support: Meta-analysis of four trials pooling immunocompetent and immunosuppressed patients: no significant association between oral nicotinamide and squamous-cell or basal-cell carcinoma; the authors judged the evidence insufficient.
- Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009;30(1):101-5. doi: 10.1093/carcin/bgn248.PubMedUsed to support: Randomized, double-blind, placebo-controlled crossover study in healthy volunteers: one week of oral nicotinamide (500 or 1,500 mg daily) significantly reduced suppression of skin immune responses by low-dose simulated sunlight and was well tolerated.
- Changes in ultraviolet B radiation-induced DNA damage and erythema after oral nicotinamide and polypodium leucotomos in healthy volunteers: an intraindividual controlled trial. Photochem Photobiol Sci. 2025;24(11):1951-1958. doi: 10.1007/s43630-025-00807-7.PubMedUsed to support: Non-randomized intraindividual study in which 47 healthy volunteers completed 30 days of nicotinamide 2,000 mg daily or a fern extract (Polypodium leucotomos), each compared before and after: nicotinamide did not change the UVB sunburn threshold or UVB-induced DNA damage (thymidine dimers) in skin or urine.
- Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial. Photochem Photobiol Sci. 2026;25(5):845-852. doi: 10.1007/s43630-026-00884-2.PubMedUsed to support: Study in 50 healthy volunteers randomized to nicotinamide 2,000 mg daily or a fern extract for 30 days, each compared before and after (no placebo): nicotinamide raised the UVA redness threshold by 26% but did not reduce UVA-induced DNA damage in skin or urine.
- Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clin Exp Ophthalmol. 2020;48(7):903-914. doi: 10.1111/ceo.13818.PubMedUsed to support: Crossover randomized trial in 57 treated glaucoma patients: nicotinamide 1.5 then 3.0 g/day (12 weeks) improved electroretinogram measures of inner retinal function within the nicotinamide period (PhNR Vmax up 14.8%, P=0.02) but not within the placebo period (up 5.2%, not significant), with a trend toward better visual fields.
- Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial. Br J Ophthalmol. 2026;110(4):417-424. doi: 10.1136/bjo-2025-328096.PubMedUsed to support: Crossover randomized trial in 53 people with normal-tension glaucoma: nicotinamide 1 then 2 g/day for 12 weeks increased two electroretinogram amplitudes more than placebo, with no difference in visual-field measures.
- The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8(1):62-73. doi: 10.1038/s42255-025-01421-8.PubMedUsed to support: Randomized, open-label, placebo-controlled 14-day study in 65 healthy adults by Nestle researchers: NR and NMN (1 g/day) raised circulating NAD+, but nicotinamide (0.5 g/day) did not; nicotinamide only acutely and briefly affected the blood NAD+ metabolome.
- Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43(11):1337-45. doi: 10.1007/s001250051536.PubMedUsed to support: Safety review: nicotinamide has a wide therapeutic index, but reversible liver toxicity has been reported at very high doses, minor liver-enzyme changes occur infrequently at diabetes-prevention doses, and minor insulin resistance has been reported; adult doses above 3 g/day should be treated as having toxic potential and unsupervised use discouraged.
- European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925-31. doi: 10.1016/S0140-6736(04)15786-3.PubMedUsed to support: Five-year randomized placebo-controlled trial in 552 antibody-positive relatives of people with type 1 diabetes: modified-release nicotinamide 1.2 g/m2 daily did not delay diabetes (adjusted hazard ratio 1.01); serious adverse events did not differ and children's growth was unaffected.
- Interactions between primidone, carbamazepine, and nicotinamide. Neurology. 1982;32(10):1122-26. doi: 10.1212/wnl.32.10.1122.PubMedUsed to support: Mouse experiments and observations in three epilepsy patients: nicotinamide slowed the conversion of primidone to phenobarbital and raised carbamazepine levels in two patients, probably by inhibiting liver cytochrome P450 enzymes.
- Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC. EFSA J. 2019;17(8):e05775. doi: 10.2903/j.efsa.2019.5775.PubMedUsed to support: EFSA opinion on nicotinamide riboside; its full text restates the EU tolerable upper intake level for nicotinamide of 900 mg/day for adults (set by the Scientific Committee on Food in 2002, not applicable in pregnancy or lactation) and confirms NR adds to the body's nicotinamide pool.
- Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogenesis. 2013;34(5):1144-9. doi: 10.1093/carcin/bgt017.PubMedUsed to support: Laboratory study in cultured human skin cells and donated human skin: nicotinamide enhanced the repair of two kinds of UV-induced DNA damage, linked to preserving cellular energy after UV. Not a study in people taking supplements.
- Niacin: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements. 2026;Online fact sheet, accessed October 2026..SourceUsed to support: Not PubMed-indexed (official NIH fact sheet). Gives the niacin RDAs (16 mg NE for men, 14 mg NE for women), the 35 mg/day adult UL that applies to both supplemental forms, states that nicotinamide does not cause flushing or change blood lipids, and lists nausea, vomiting and liver toxicity at 3,000 mg/day and diarrhea and low platelets in hemodialysis patients.